Zoetis Inc. (ZTS), a drug maker, on Tuesday revised up its annual guidance above analysts' estimates to reflect the impact of foreign exchange and enacted tariffs.
For the full-year 2025, the company now expects net profit of $2.630 billion to $2.680 billion, or $5.85 to $5.95 per share against its earlier guidance of $2.570 billion to $2.620 billion, or $5.70 to $5.80 per share.
Excluding items, annual earnings are now projected to be in the range of $2.775 billion to $2.825 billion, or $6.20 to $6.30 per share, higher than previous guidance of $2.700 billion to $2.750 billion, or $6 to $6.10 per share.
On average, analysts polled forecast the firm to earn $6.06 per share for the year. Analysts' estimates typically exclude special items.
Zoetis now projects annual revenue of $9.425 billion to $9.575 billion, higher than the earlier expectation of $9.225 billion to $9.375 billion, and current analysts' forecast of $9.33 billion.
ZTS was up by 2.49 percent at $162 in the pre-market trade on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.